{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:04:19Z","timestamp":1762459459210},"reference-count":25,"publisher":"Impact Journals, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,2,21]]},"DOI":"10.18632\/oncotarget.14531","type":"journal-article","created":{"date-parts":[[2017,1,8]],"date-time":"2017-01-08T15:05:47Z","timestamp":1483887947000},"page":"13367-13374","source":"Crossref","is-referenced-by-count":6,"title":["Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)"],"prefix":"10.18632","volume":"8","author":[{"given":"Dok Hyun","family":"Yoon","sequence":"first","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong Seok","family":"Sohn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dong-A University Hospital, Busan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Sik","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Min","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,1,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014","volume":"26","author":"Miller","year":"2008","journal-title":"J Clin Oncol"},{"key":"2","first-page":"iv99","article-title":"Limited-stage DLBCL patients with a negative FDG-PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone","volume":"19","author":"Connors","year":"2008","journal-title":"Ann Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Fisher","year":"1998","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol","volume":"16","author":"Ribrag","year":"2005","journal-title":"Ann Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Norbert","year":"2002","journal-title":"Ann Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5045\/br.2014.49.2.115","article-title":"Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection","volume":"49","author":"Suh","year":"2014","journal-title":"Blood Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bjh.13766","article-title":"Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era","volume":"171","author":"Zelenetz","year":"2015","journal-title":"Br J Haematol"},{"key":"9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Ho","year":"2008","journal-title":"Lancet Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Gascoyne","year":"2015","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-014-2115-z","article-title":"The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab","volume":"93","author":"Suh","year":"2014","journal-title":"Ann Hematol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood-2010-06-288480","article-title":"Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone","volume":"117","author":"Hwang","year":"2011","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jso.21927","article-title":"Surgical resection combined with chemotherapy can help achieve better outcomes in patients with primary colonic lymphoma","volume":"104","author":"Chang","year":"2011","journal-title":"J Surg Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3346\/jkms.2014.29.1.53","article-title":"Intestinal diffuse large B-cell lymphoma: an evaluation of different staging systems","volume":"29","author":"Huh","year":"2014","journal-title":"J Korean Med Sci"},{"key":"15","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","article-title":"Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB","volume":"126","author":"Rizo","year":"2015","journal-title":"DLBCL. Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Casasnovas","year":"2013","journal-title":"Lancet Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Kruger","year":"2013","journal-title":"Lancet"},{"key":"18","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","article-title":"Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736","volume":"34","author":"Smith","year":"2016","journal-title":"J Clin Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Muggia","year":"1979","journal-title":"Ann Intern Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-125-1-199607010-00008","article-title":"Anthracycline-induced cardiotoxicity","volume":"125","author":"Young","year":"1996","journal-title":"Ann Intern Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.2003.04749.x","article-title":"Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation\u2014a population-based study of 1575 cases","volume":"124","author":"Christensen","year":"2004","journal-title":"Br J Haematol"},{"key":"22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Syrbu","year":"2014","journal-title":"J Clin Oncol"},{"key":"23","unstructured":"Swerdlow, Campo, Harris, Jaffe, Pileri, Stein, Thiele, Vardiman. WHO classification of tumours haematopoietic and lymphoid tissues: International Agency for Research on Cancer. 2008."},{"key":"24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Gisselbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Lister","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T16:32:52Z","timestamp":1589128372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,5]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,2,21]]}},"alternative-id":["14531","28076329"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14531","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,5]]}}}